[go: up one dir, main page]

WO2006067198A3 - Targeted use of engineered enzymes - Google Patents

Targeted use of engineered enzymes Download PDF

Info

Publication number
WO2006067198A3
WO2006067198A3 PCT/EP2005/057061 EP2005057061W WO2006067198A3 WO 2006067198 A3 WO2006067198 A3 WO 2006067198A3 EP 2005057061 W EP2005057061 W EP 2005057061W WO 2006067198 A3 WO2006067198 A3 WO 2006067198A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeted use
engineered enzymes
disease
defined specificity
engineered
Prior art date
Application number
PCT/EP2005/057061
Other languages
French (fr)
Other versions
WO2006067198A2 (en
Inventor
Ulrich Haupts
Andre Koltermann
Andreas Scheidig
Ulrich Kettling
Wayne Michael Coco
Original Assignee
Direvo Biotech Ag
Voetsmeier Christian
Ulrich Haupts
Andre Koltermann
Andreas Scheidig
Ulrich Kettling
Wayne Michael Coco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direvo Biotech Ag, Voetsmeier Christian, Ulrich Haupts, Andre Koltermann, Andreas Scheidig, Ulrich Kettling, Wayne Michael Coco filed Critical Direvo Biotech Ag
Priority to EP05823713A priority Critical patent/EP1827486A2/en
Publication of WO2006067198A2 publication Critical patent/WO2006067198A2/en
Publication of WO2006067198A3 publication Critical patent/WO2006067198A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides method for the treatment of a disease by applying a medicament comprising a protease with a defined specificity is capable to hydrolyze specific peptide bonds within a target substrate related to such disease. The proteases with such a defined specificity can further be used for related therapeutic or diagnostic purposes.
PCT/EP2005/057061 2004-12-22 2005-12-21 Targeted use of engineered enzymes WO2006067198A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05823713A EP1827486A2 (en) 2004-12-22 2005-12-21 Targeted use of engineered enzymes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106903 2004-12-22
EP04106903.0 2004-12-22

Publications (2)

Publication Number Publication Date
WO2006067198A2 WO2006067198A2 (en) 2006-06-29
WO2006067198A3 true WO2006067198A3 (en) 2007-01-04

Family

ID=36602119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/057061 WO2006067198A2 (en) 2004-12-22 2005-12-21 Targeted use of engineered enzymes

Country Status (2)

Country Link
EP (1) EP1827486A2 (en)
WO (1) WO2006067198A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266724B2 (en) 2019-08-15 2022-03-08 Catalyst Biosciences, Inc. Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
DK1735439T3 (en) 2004-04-12 2012-02-06 Catalyst Biosciences Inc Cleavage of VEGF and VEGF receptor by wild-type and mutant MT-SP1
ES2611608T3 (en) 2005-10-21 2017-05-09 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
TWI369402B (en) 2006-07-05 2012-08-01 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
TWI465247B (en) 2008-04-11 2014-12-21 Catalyst Biosciences Inc Modified Factor VII polypeptide and use thereof
WO2010129287A2 (en) 2009-04-27 2010-11-11 The Board Of Trustees Of The University Of Illinois Hemicellulose-degrading enzymes
KR101511737B1 (en) * 2012-12-31 2015-04-20 대한민국 Pharmaceutical composition for prevention and treatment of degenerative brain diseases comprising inhibitor of SUMO1 and BACE1 interaction as an active ingredient
JP6200087B2 (en) * 2013-12-17 2017-09-20 ノヴォ ノルディスク アー／エス Enterokinase-cleavable polypeptide
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
FI3273986T3 (en) 2015-03-27 2024-02-07 Immatics Biotechnologies Gmbh NEW PEPTIDES AND PEPTIDE COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT CANCER
US12234464B2 (en) 2018-11-09 2025-02-25 Ginkgo Bioworks, Inc. Biosynthesis of mogrosides
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKADE OF GALECTIN-3
CN120230734B (en) * 2025-06-03 2025-07-29 山东三元生物科技股份有限公司 Sucrose phosphorylase mutant and application thereof in synthesis of 2-O-alpha-D-glucopyranosyl-L-ascorbic acid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
WO2003095670A2 (en) * 2002-05-10 2003-11-20 Direvo Biotech Ag Process for generating sequence-specific proteases by directed evolution and use thereof
WO2004067737A2 (en) * 2003-01-30 2004-08-12 Novozymes A/S Subtilases
WO2004113521A1 (en) * 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
WO2003095670A2 (en) * 2002-05-10 2003-11-20 Direvo Biotech Ag Process for generating sequence-specific proteases by directed evolution and use thereof
WO2004067737A2 (en) * 2003-01-30 2004-08-12 Novozymes A/S Subtilases
WO2004113521A1 (en) * 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALTAMIRANO M M ET AL: "Directed evolution of new catalytic activity using the alpha/beta-barrel scaffold", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 403, no. 6770, 10 February 2000 (2000-02-10), pages 617 - 622, XP002173865, ISSN: 0028-0836 *
COOMBS G.S.: "Directing sequence-specific proteolysis to new targets.", J BIOL. CHEM., vol. 273, no. 8, 20 February 1998 (1998-02-20), pages 4323 - 4328, XP002401171 *
HEDSTROM E ET AL: "CONVERTING TRYPSIN TO CHYMOTRYPSIN: THE ROLE OF SURFACE LOOPS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 255, no. 5049, 6 March 1992 (1992-03-06), pages 1249 - 1253, XP001179164, ISSN: 0036-8075 *
KURTH T ET AL: "Engineering the S1' subsite of trypsin: design of a protease which cleaves between dibasic residues", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 37, 18 August 1998 (1998-08-18), pages 11434 - 11440, XP002218040, ISSN: 0006-2960 *
SICES H J AND KRISTIE T M: "A genetic screen for the isolation of site-specific proteases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 95, March 1998 (1998-03-01), pages 2828 - 2833, XP002306297, ISSN: 0027-8424 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266724B2 (en) 2019-08-15 2022-03-08 Catalyst Biosciences, Inc. Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Also Published As

Publication number Publication date
EP1827486A2 (en) 2007-09-05
WO2006067198A2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
WO2006067198A3 (en) Targeted use of engineered enzymes
NZ595193A (en) Modified Proteases That Inhibit Complement Activation
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
WO2007081516A3 (en) Tumor activated prodrugs
MXPA05003493A (en) Methods of generating and screenign for porteases with altered specificity.
EP2175834B8 (en) Glp-1-fc fusion protein formulation
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
WO2007117482A3 (en) Renin inhibitors
WO2006052718A3 (en) Farnesyltransferase inhibitors for treating sepsis
WO2005118634A3 (en) Helical peptidomimetics with enhanced activity against beta-amyloid production
WO2004065423A3 (en) Recognition molecules for the treatment and detection of tumours
WO2010074588A8 (en) Pharmaceutical compounds
WO2008033562A3 (en) Kinase inhibitor compounds
WO2004010937A3 (en) Method of treating cancer
WO2007117557A3 (en) Diaminopropanol renin inhibitors
WO2005120476A3 (en) Novel use of peptide compounds for treating amyotrophic lateral sclerosis
DE60320095D1 (en) COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006114105A3 (en) Use of modified factor vii for treating bleeding
WO2007121124A3 (en) Hcv inhibitors comprising beta amino acids and their uses
MX2007008065A (en) Compositions and methods for modulating gene expression using self-protected oligonucleotides.
WO2009001743A1 (en) Novel adamts-13 mutant
WO2007117559A3 (en) Renin inhibitors
WO2007099348A3 (en) Cathepsin propeptide and uses thereof
WO2009132149A3 (en) Treatment of conditions related to cecal ligation shock

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005823713

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005823713

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005823713

Country of ref document: EP